Schneider Lab

https://news.iu.edu/live/news/37840-iu-research-targets-debilitating-side-effects-for

IU research targets debilitating side effects for Black breast cancer patients IU researchers are leading the way to improving quality of life and curative chemotherapy doses for Black patients with breast cancer — with help from t...

https://www.komen.org/blog/personalized-chemo/

Personalizing Chemotherapy for Black Women - Susan G. Komen® Komen Scholar Bryan Schneider, M.D., trial lead for the EAZ171 clinical trial, is seeking to overcome these disparities in outcomes for Black women with breast cancer by personalizing chemotherapy.